2024-05-17 10:44:05 ET
Summary
- The latest period was a rollercoaster ride for Arrowhead Pharmaceuticals despite significant fundamental developments.
- Phase 3 results of plozasiran in FCS patients should lead to Arrowhead finally becoming a commercial-stage company in 2025.
- The bar for plozasiran is set by Ionis' olezarsen in terms of APOC3 and triglyceride reductions as well as the reduction in the risk of acute pancreatitis.
- Plozasiran in FCS represents a small but important step for Arrowhead's cardiometabolic pipeline which is set to expand later this year with the addition of two new clinical candidates.
- ARWR needs to do a better job managing expectations or executing on its promised timelines.
Arrowhead Pharmaceuticals Overview
The latest period was a rollercoaster ride for Arrowhead Pharmaceuticals, Inc. ( ARWR ). I argued in late 2023 that the company needed to address the financing overhang, and it did just that in early January by completing a sizable follow-on offering, but shortly after the offering, it also announced a pipeline prioritization. This may have been disappointing for some investors, but I believe it was the right decision to deprioritize some non-core assets and try to partner them....
Read the full article on Seeking Alpha
For further details see:
Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point